NeOnc Technologies Holdings is trading 9.3% down now at $4.98 after a sharp multi-session rally.
- The stock gained 31.46% on August 14, 16.35% on August 17, and 12.63% on August 18.
- The advance followed positive Phase 2a NEO100 glioma results, including 48.9% six-month progression-free survival versus a 20% benchmark.
- No stronger company-specific announcement explaining the August 19 decline was identified.